Michael McElhaugh
Algemeen Directeur bij ARBUTUS BIOPHARMA CORPORATION
Vermogen: 4 M $ op 30-04-2024
Actieve functies van Michael McElhaugh
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Directeur/Bestuurslid | 01-01-2024 | - |
| Algemeen Directeur | 01-01-2024 | - | |
| Operationeel Directeur | 01-11-2022 | - | |
| President | 01-01-2024 | - | |
| Corporate Officer/Principal | 01-12-2018 | 01-11-2022 | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Algemeen Directeur | 01-01-2024 | - |
| President | 01-01-2024 | - |
Loopbaan van Michael McElhaugh
Eerdere bekende functies van Michael McElhaugh
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01-09-2008 | 01-03-2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Operationeel Directeur | 01-05-2012 | - |
| Oprichter | 01-05-2012 | - |
Opleiding van Michael McElhaugh
| St. Joseph's University | Undergraduate Degree |
| Thomas Jefferson University | Graduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 8 |
Operationeel
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 2 |
| Chief Executive Officer | 2 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
- Beurs
- Insiders
- Michael McElhaugh
- Ervaring
